• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.

作者信息

Kontoghiorghes George J

出版信息

Hemoglobin. 2008;32(6):608-15. doi: 10.1080/03630260802341703.

DOI:10.1080/03630260802341703
PMID:19065341
Abstract
摘要

相似文献

1
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.对于地拉罗司的致命或严重毒性风险、低疗效和高价格，提高透明度并提供全面信息，可能会增加全球改善铁螯合治疗的前景。
Hemoglobin. 2008;32(6):608-15. doi: 10.1080/03630260802341703.
2
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Hemoglobin. 2008;32(6):601-7. doi: 10.1080/03630260802342008.
3
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.铁螯合疗法的伦理问题及风险/效益评估：去铁酮/去铁胺联合疗法的进展以及对地拉罗司安全性、有效性和成本的担忧。
Hemoglobin. 2008;32(1-2):1-15. doi: 10.1080/03630260701726533.
4
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.每日交替使用地拉罗司和去铁酮疗法治疗“难以螯合”的重型β地中海贫血患者。
Am J Hematol. 2010 Jun;85(6):460-1. doi: 10.1002/ajh.21711.
5
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.介绍更高剂量的地拉罗司：疗效更好，但不能有效去除心脏中的铁，且严重毒性风险增加。
Expert Opin Drug Saf. 2010 Jul;9(4):633-41. doi: 10.1517/14740338.2010.497138.
6
Deferasirox (Exjade): a new iron chelator.地拉罗司（恩瑞格）：一种新型铁螯合剂。
Med Lett Drugs Ther. 2006 Apr 24;48(1233):35-6.
7
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.地拉罗司用于治疗慢性贫血患者因定期输血导致的铁过载（输血性含铁血黄素沉着症）：一项系统评价与经济学评估
Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010.
8
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.β-地中海贫血慢性铁过载患者地拉罗司的终生成本-效用分析：英国视角。
Clin Drug Investig. 2012 Dec;32(12):805-15. doi: 10.1007/s40261-012-0008-2.
9
Management of the thalassemias.地中海贫血症的治疗管理。
Cold Spring Harb Perspect Med. 2013 Jun 1;3(6):a011767. doi: 10.1101/cshperspect.a011767.
10
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.比较去铁酮与去铁胺在镰状细胞病中的疗效和安全性：包括药代动力学和同时使用羟基脲的两年结果。
Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

引用本文的文献

1
Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs.欧盟与美国在药品监管事务上的差异影响全球患者安全标准和公众健康意识：以地拉罗司及其他铁螯合剂药物为例
Medicines (Basel). 2021 Jul 7;8(7):36. doi: 10.3390/medicines8070036.
2
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016.
3
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
4
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.